Ketamine Therapy for Depression: What to Expect, Cost, and How to Find a Provider

Ketamine-based treatments for depression have entered a decisive new phase. In January 2025, the FDA approved Spravato as a standalone monotherapy for treatment-resistant depression — the first time the agency has approved a standalone treatment for that indication. More than 1,500 ketamine clinics now operate across the country. And 2025 produced some of the most significant mechanistic research in the field's history.

But access remains deeply uneven. Out-of-pocket costs for IV ketamine still run $400–$800 per session. Clinics are concentrated in urban centers. And racial disparities in who actually receives treatment are documented and large.

Here's what the science, protocols, costs, and insurance landscape actually look like in 2026.

---

How Ketamine Works for Depression

The traditional explanation has been well-established for years: ketamine blocks NMDA receptors, triggering a surge of glutamate that drives rapid synaptogenesis — the formation of new synaptic connections in the brain. This mechanism accounts for ketamine's speed advantage over conventional antidepressants, which require weeks of daily dosing to produce effects that ketamine can achieve within hours.

But 2025 research expanded the picture significantly.

Adenosine as a unifying mechanism. A November 2025 study by Yue et al. (Nature, 649: 423–431) discovered that ketamine induces adenosine surges in the medial prefrontal cortex and hippocampus. Critically, disrupting adenosine receptors abolished the therapeutic effect entirely. The researchers propose adenosine signaling as a unifying mechanism underlying ketamine's antidepressant action.

Extending the duration of effect. A May 2025 study by Ma et al. (Science, 388: 646–655) identified that enhancing ERK activity through DUSP6 inhibition extended ketamine's antidepressant effects from days to up to two months in animal models, with a 157% increase in synaptic potentiation. This finding points toward future combination approaches that could dramatically extend ketamine's duration of benefit.

The emerging consensus is that multiple pathways converge: NMDA blockade on interneurons, AMPA receptor activation, BDNF-TrkB-ERK cascades, and adenosine signaling. No single mechanism tells the whole story.

---

Who Ketamine Therapy Is For

Treatment-resistant depression (TRD) is the primary indication for ketamine. TRD is conventionally defined as an inadequate response to at least two oral antidepressants, each at an adequate dose for 6–8 weeks. This affects an estimated 30% of people with major depressive disorder — a large population for whom conventional first- and second-line treatments have failed.

Ketamine is also used off-label for:

• Major depressive disorder with suicidal ideation
• Anxiety disorders
• PTSD (addressed in detail in our ketamine therapy for PTSD guide)
• Chronic pain conditions

No referral is required to access IV ketamine at most clinics. Spravato, the FDA-approved esketamine nasal spray, typically requires a prescribing psychiatrist to document prior treatment failures.

---

What Treatment Actually Looks Like

IV Ketamine

The core IV protocol has been unchanged since its widespread adoption: 0.5 mg/kg infused over 40 minutes. Standard induction is six infusions over 2–3 weeks. The VA protocol specifies no more than twice weekly over four weeks.

After each infusion, patients are monitored for 120 minutes. Driving is prohibited for the remainder of the day. Dissociation and sedation are common during the infusion itself and typically resolve within the monitoring period.

Spravato (Esketamine)

Spravato is self-administered as a nasal spray in doses of 56 mg or 84 mg. The standard protocol is twice weekly for the first four weeks, then weekly, then every one to two weeks for maintenance. Each session requires two hours of in-office monitoring at a REMS-certified facility — you cannot take Spravato at home.

Emerging Delivery Methods (Not Yet FDA-Approved)

Two alternative delivery approaches are in clinical development but not yet approved:

• R-107 oral extended-release tablet: Phase 2 results showed a relapse rate of 42.9% versus 70.6% for placebo in patients who responded to IV ketamine
• Subcutaneous injection: Being evaluated in the KADS study

Neither is currently available outside of clinical trials.

---

What the Efficacy Data Actually Shows

IV Racemic Ketamine

The most comprehensive meta-analysis of IV ketamine for depression — Alnefeesi et al. (Journal of Psychiatric Research, 2022), analyzing 2,665 patients across 79 studies — found a response rate of approximately 45% and a remission rate of approximately 30%. These figures are for a single induction course; ongoing maintenance can sustain response in many patients.

For comparison, the standard-of-care benchmark matters: ECT (electroconvulsive therapy) has historically been the gold standard for severe TRD. The ELEKT-D trial published in NEJM in 2023 (N=403) found that IV ketamine outperformed ECT, with a response rate of 55.4% and remission rate of 38%.

Spravato

TRANSFORM-2 trial (combination therapy with oral antidepressant): 69.3% response and 52.5% remission at day 28.

TRD4005 monotherapy trial (378 adults, 51 US sites): This is the study supporting the January 2025 FDA approval. Remission was 22.5% for Spravato versus 7.6% for placebo, with measurable improvements within 24 hours. Published in JAMA Psychiatry in 2025.

ESCAPE-TRD trial (NEJM, October 2023, N=676): Esketamine outperformed quetiapine augmentation — remission 27.1% versus 17.6% at week 8.

SUSTAIN-3 long-term data (N=1,110, mean follow-up 31.5 months): 46.1% remission at endpoint, suggesting durable benefit for a substantial subset of patients.

An Honest Look at the Debate

Not all researchers agree the effect sizes are clinically meaningful. Fountoulakis and Schatzberg (AJP, March 2025) argued that adjunctive esketamine effect sizes are only 0.15–0.23. A meta-analysis by Naudet and Cristea (BMC Medicine, November 2025) found an adjunctive benefit of −2.94 MADRS points — statistically significant but below the threshold typically considered clinically significant.

The monotherapy data from the TRD4005 trial looks more compelling. That's the context behind the January 2025 FDA approval: the monotherapy data was strong enough to support approval as a standalone treatment, separate from the adjunctive use debate.

---

Cost: What You'll Actually Pay

For a detailed breakdown with state-by-state data, see our complete ketamine therapy cost guide.

IV Ketamine

• Per session: $400–$800 nationally
• 6-session induction: $2,400–$4,800
• Premium metro markets (NYC, LA, SF): $600–$1,000+ per session
• Rural providers: as low as $350 per session
• Price trend: Increased 10–15% from 2023, then stabilized in 2025

State-level cost data is available for California and Texas, where price variation within a single state can be substantial.

Spravato With Insurance

Spravato retail medication costs run $882–$1,663 per dose depending on strength, plus $300–$700+ in mandatory REMS observation fees. However, most commercially insured patients pay far less. The J&J "Spravato withMe" savings program reduces the medication copay to $10 per treatment for eligible commercially insured patients, and a separate Observation Rebate Program covers monitoring costs after rebate — meaning eligible patients may pay as little as $10 per session total. Without the savings program, coinsurance can be substantially higher. The withMe program is not available for Medicare, Medicaid, TRICARE, or VA patients.

At-Home Sublingual Options

Several telehealth platforms offer compounded sublingual ketamine for at-home use:

Platform	Cost	States
Joyous	$129/month (daily low-dose)	27 states
Better U	$100/session	29 states
Mindbloom	$215/session	35 states
Innerwell	$54–$81/session (with select insurance)	CA, NY, WA, CO, TX, IL

All at-home providers accept HSA/FSA. Note that at-home compounded ketamine is not FDA-approved for psychiatric use — the FDA issued a warning in October 2023 stating that "ketamine is not FDA approved for the treatment of any psychiatric disorder."

---

Insurance Coverage

Spravato

A cross-sectional analysis by Alvear et al. (SSRN, August 2025) covering 85.9 million insured members found that 100% of 18 major US commercial insurers cover Spravato for its FDA-approved indications. 94.4% require prior authorization.

Insurers with documented Spravato coverage include BCBS, Aetna, UnitedHealthcare, Cigna, Humana, Anthem, HealthNet, and Tricare.

Medicare Part B covers 80% of Spravato costs. After a $257 deductible, patients typically pay $140–$240 per session. Medicare does not cover IV ketamine for psychiatric conditions.

Medicaid generally covers Spravato, though specifics vary by state.

Important caveat — treatment deserts: A 2023 analysis found that only 26 states had any clinic-billed Medicare esketamine services, leaving a 24-state "Medicare treatment desert" where access is effectively unavailable for Medicare beneficiaries even when coverage exists on paper.

Kaiser Permanente is a notable exception among major insurers: it also covers IV infusions in select circumstances.

IV Ketamine

Only approximately 1.2% of covered lives — representing a single insurer with roughly 1.7 million members — have explicit IV ketamine coverage for depression. Coverage for IM or oral ketamine for psychiatric use is effectively zero across major commercial plans.

---

Safety: The Real-World Data

The largest real-world safety analysis of esketamine was published by Sanacora et al. in AJP in October 2025. It covered 58,483 patients across 1,486,213 sessions over nearly five years.

Key findings:

• Dissociation occurred in 41% of sessions
• Sedation occurred in 34.7% of sessions
• Clinically significant blood pressure increases: 0.9% of sessions
• Serious adverse events: fewer than 0.1% of sessions
• Among 210 cases of all-cause drug abuse or misuse, none were attributed to esketamine itself
• Dissociation decreased with repeated treatment: CADSS scores dropped from 6.7 to 2.9 over the first four weeks

The large dataset and extended follow-up make this the most definitive real-world safety evidence available. The side effect profile is significant but manageable, and serious events are rare.

---

Who Is and Isn't Getting Access

Approximately 1,500–2,000 ketamine clinics now operate in the US — up from fewer than 100 in 2015. But access is not evenly distributed.

Clinics are heavily concentrated in urban centers, and the patient population receiving ketamine skews significantly toward higher income brackets ($70,000–$140,000 annually). A large study by Liu et al. (Psychiatric Services, June 2025, N=861,179) documented stark racial disparities: Black patients were 25% less likely to receive ketamine, Hispanic patients 29% less likely, and Asian patients 35% less likely, compared to white patients with equivalent diagnoses.

These aren't small disparities. They reflect structural access barriers — cost, geography, and likely provider bias — that the growth in clinic count hasn't resolved.

---

Finding a Provider

Patients find ketamine providers through online directories, the Spravato.com REMS locator for certified esketamine providers, telehealth platforms, and physician referrals. No referral is required for IV ketamine at most clinics.

Questions worth asking before your first appointment:

• What is the per-session cost for the full induction protocol, and is package pricing available?
• Do you provide a superbill for out-of-network insurance reimbursement?
• Do you accept HSA/FSA?
• What monitoring is included, and are any medications (anti-nausea, etc.) billed separately?
• Do you offer integration support or referrals to therapists familiar with ketamine?

Search our directory to find a verified ketamine clinic near you →

---

The Bottom Line

Ketamine's evidence base for treatment-resistant depression is now substantial — strong enough to support an FDA monotherapy approval in 2025, and backed by a large and growing real-world safety dataset. The 2025 mechanistic discoveries (adenosine signaling, ERK pathway extension) are expanding what researchers understand about why it works and how to make it work longer.

The access problem is real. IV ketamine remains almost entirely self-pay, costs $2,400–$4,800 for a standard induction, and is concentrated in cities. Spravato has dramatically better insurance coverage but requires in-person visits to REMS-certified facilities, which are also not uniformly distributed.

For patients who have tried two or more antidepressants without adequate relief, ketamine is worth a serious evaluation — starting with a conversation about Spravato coverage if you have commercial insurance, and IV ketamine if you're self-pay or treating something other than TRD.

If you're also exploring other options, psilocybin therapy is now legally accessible in Oregon, Colorado, New Mexico, South Dakota, and Minnesota — see our guide to psilocybin therapy legal states.

For a full comparison of IV ketamine versus Spravato on cost, efficacy, and insurance, see Spravato vs. Ketamine: Which Is Right for You?

---

---

Sources

• Yue et al. Adenosine signalling drives antidepressant actions of ketamine. Nature, 2025
• Ma et al. DUSP6 inhibition extends ketamine's antidepressant effects via ERK. Science, 2025
• Alnefeesi Y et al. Real-world effectiveness of ketamine for TRD (2,665 patients, 79 studies). Journal of Psychiatric Research, 2022
• Anand A et al. ELEKT-D: IV ketamine vs. ECT (N=403). NEJM, 2023
• Ochs-Ross R et al. TRD4005 monotherapy trial — esketamine vs. placebo (N=378). JAMA Psychiatry, 2025
• Morriss R et al. ESCAPE-TRD: esketamine vs. quetiapine augmentation (N=676). NEJM, 2023
• Fountoulakis KN, Schatzberg AF et al. Critique of adjunctive esketamine effect sizes. AJP, 2025
• Naudet F, Cristea IA et al. Adjunctive esketamine meta-analysis. BMC Medicine, 2025
• Sanacora G et al. Real-world esketamine safety analysis (58,483 patients, 1.49M sessions). AJP, 2025
• Liu M et al. Racial-ethnic disparities in ketamine access (N=861,179). Psychiatric Services, 2025
• Alvear M. Insurance coverage of Spravato across 18 major US commercial insurers. SSRN preprint, 2025
• Levinta A et al. R-107 oral ketamine Phase 2 BEDROC trial. Nature Medicine, 2024

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning any treatment program. Clinical data cited reflects published peer-reviewed research as referenced.